® ROCKWELL | --- | --- | --- | --- | --- | |---------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | ROCKWELL MEDICAL, INC. | | | | | | TRANSFORMING IRON DEFICIENCY AND ANEMIA MANAGEMENT March 2021 | | | | | FORWARD-LOOKING STATEMENTS 2 Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell Medical's intention to commercialize Triferic® Dia ...

Start Time: 16:30 January 1, 0000 5:13 PM ET Â Rockwell Medical, Inc. (NASDAQ:RMTI) Q3 2020 Earnings Conference Call November 09, 2020, 16:30 PM ET Company Participants Russell Ellison - President and CEO Russell Skibsted - EVP, CFO and Chief Business Officer Marc Hoffman - CMO Tim Chole - VP, Marketing Claudia Styslinger - IR, Argo Partners Conference Call Participants Brandon Folkes - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the R ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q2 2020 Earnings Conference Call November 9, 2020 4:20 PM ET Company Participants Claudia Styslinger – Investor Relations Russell Ellison - President, Chief Executive Officer & Director Tim Chole – Vice President, Marketing Russell Skibsted - Executive Vice President, Chief Financial Officer & Chief Business Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Blair Cohen - H.C. Wainwright & Co. Disclaimer: *NEW* We are providing this transcript ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|------------------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | Q3 2020 FINANCIAL RESULTS AND BUSINESS UPDATE | | | | | | | | CALL PARTICIPANTS | --- | --- | |---------------------------------------|-------------------------------------------------| | Russell Ellison, M.D., M.Sc. | President and Chief Executive Officer | | Russell Skibsted | Chief Financial Officer, Chief Busine ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Claudia Styslinger - Assistant Vice President at Argot Partners, LLC Russell Ellison - President and Chief Executive Officer Marc Hoffman - Chief Medical Officer Tim Chole - Vice President of Marketing Angus Smith - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald L.P. Blair Cohen - HC Wainwright Operator Good afternoon, ladies and gentlemen, and thank you ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2019 Earnings Conference Call March 12, 2020 4:30 PM ET Company Participants Judy DiClemente - Investor Relations Stuart Paul - Chief Executive Officer Angus Smith - Chief Financial Officer Conference Call Participants Edward Marks - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the Rockwell Medical 2019 Q4 Results Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and ins ...

Triferic Overview - Rockwell Medical is a commercial-stage company focused on transforming anemia management, initially targeting ESRD[7] - Triferic is designed to replace iron and maintain hemoglobin without increasing ferritin levels[7] - The global Triferic market potential is estimated to exceed $1 billion[7] Triferic Clinical and Commercial Progress - Dialysate Triferic was launched in the U S in May 2019[10] - An NDA for I V Triferic was submitted in May 2019, with a PDUFA date of March 28, 2020[10, 13] - Clinical data is being collected from seven sites with over 500 patients, with initial data expected in Q1 2020[12] - Clinics adopting Triferic have shown a 75% conversion rate since launch[18] Market and Financial Position - Rockwell Medical generates over $60 million in annual revenue from dialysis concentrates[7] - The U S market for anemia management therapies in CKD is over $4 1 billion annually[40] - The company is the 2 supplier of dialysis concentrates in the U S [7] International Expansion - Partnerships are in place for Triferic in China, India, Canada, Peru, and Chile[11] - The estimated peak market opportunity in China is over $400 million[52] - The estimated peak market opportunity in Europe and Japan is over $600 million[53]

Rockwell Medical, Inc. (NASDAQ:RMTI) Q3 2019 Results Conference Call November 11, 2019 4:30 PM ET Company Participants Judy DiClemente - In-Site Communications, Investor Relations Stuart Paul - President and Chief Executive Officer Angus Smith - Chief Financial Officer John McLaughlin - Chairman Conference Call Participants Brandon Folkes - Cantor Fitzgerald Chris Raymond - Piper Jaffray Edward Marks - H.C. Wainwright Operator Good day, ladies and gentlemen. And welcome to the Rockwell Medical 2019 Q3 Resul ...

Triferic Product & Market Opportunity - Triferic is the FIRST and ONLY FDA-approved therapy indicated to maintain hemoglobin levels in hemodialysis patients[5, 66] - Global Triferic market potential exceeds $1 billion[5, 10, 51, 52] - The U S market potential for Triferic is estimated at $400 million[47] - The company's base business generates over $60 million in revenue annually[5] Commercialization & Strategy - Dialysate Triferic U S commercial launch commenced in May 2019, establishing a foundation for I V Triferic[5, 14] - I V Triferic NDA was submitted in May 2019 with a PDUFA date of March 28, 2020[5, 14, 33] - The company is building a commercial and medical team of approximately 25 professionals to support Triferic adoption[41] Financial Performance - The company's sales were $63 4 million in FY 2018 and $57 3 million in FY 2017[56] - The operating loss was $32 4 million in FY 2018 and $25 9 million in FY 2017[57] - The company's cash and investments were $33 5 million[59]

Rockwell Medical, Inc. (NASDAQ:RMTI) Q2 2019 Results Conference Call August 8, 2019 4:30 PM ET Company Participants Ilanit Allen – Investor Relations Stuart Paul – President and Chief Executive Officer Angus Smith – Chief Financial Officer Conference Call Participants Nicole Gabreski – Piper Jaffray David Bouchey – IFS Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Rockwell Medical 2019 Second Quarter Results Call. At this time all participants are in a listen-only mode. Later, ...